Tubulin/HDAC-IN-1

Tubulin/HDAC-IN-1 (Compound 12a, 72 h) shows cytotoxicity against various human cancer cell lines with an averaged IC₅₀ value of 0.6 nM^[1].
Tubulin/HDAC-IN-1 (2 nM, 24 h) induces HT29 cell cycle arrest in the G2/M phase and produces caspase-induced apoptosis of HT29 cells through mitochondrial dysfunction^[1].
Tubulin/HDAC-IN-1 selectively inhibits HDAC8 (IC₅₀: 150 nM), inhibits HDAC6 and HDAC11 with IC ₅₀ values of 1 μM and 1.9 μM respectively^[1].
Tubulin/HDAC-IN-1 (0.5-100 nM, 24 h/30 min) dose-dependently increases γH2AX level and acetylated SMC3 in HT-29 cells^[1].
Tubulin/HDAC-IN-1 (5-15 μΜ, 0-40 min) inhibits tubulin polymerization in a dose-dependent manner, with a maximal effect achieved at 10 μM^[1].
Tubulin/HDAC-IN-1 (250 nM, 30 min) depolymerizes the cell microtubule network, and the effect is not specific^[1].
Tubulin/HDAC-IN-1 shows good in vitro metabolic stability expressed by the intrinsic clearance CLint (given in μL/min/mg protein) using rat liver microsomes (RLM) and human liver microsomes (HLM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.